Jon Block: Thanks for the time guys.
Tim Herbert: Thanks, Jon.
Operator: Thank you. And I show our last question comes from the line of Suraj Kalia from Oppenheimer & Co. Please go ahead.
Suraj Kalia: Gentlemen, can you hear me all right?
Tim Herbert: Yes, Suraj. How are you?
Suraj Kalia: Tim, congrats on a nice quarter. So Tim — I guess, the first question for Rick. Rick, you mentioned 70/30 split between same-store new store sales? If you could just refine it a little further, maybe in terms of implants per quarter per site. Should I think about FY 2023 exiting, let’s say, round numbers, $6 million, $20 million, give or take, there was a $200 million year-over-year pop. 70% of it comes from same site. Is that the right way to think about it? Or is some other math that you’re applying to 70/30 split?
Rick Buchholz: Yeah, Suraj, thanks for the question. What I’m talking about is the percentage of our growth, not of the composition of our revenue, but more of the growth came from 70% from our existing centers and the remaining 30% from new centers.
Suraj Kalia: Okay. Fair enough. And Tim, just more on a pedantic level. The average number of days of CPAP usage that is documented by a potential patient, let’s say Suraj comes in, he’s either failed or intolerant of CPAP. When you file the documentation, what are the average number of days of failure or intolerance shown for getting a GNS authorization? Thank you for taking my questions.
Tim Herbert: Thanks, Suraj. Suraj, I think that that’s all over the place, that last number. For the most part, the patients who come in to receive Inspire therapy are not tolerant to Inspire — I’m sorry, are not tolerant to CPAP, therefore, they have zero utilization. And very few come in, if they are using CPAP to the numbers, what is it four nights — four hours a night for five of seven nights, and if they’re compliant to that, it’s kind of difficult to get insurance approval because they’re compliance to CPAP. So, the majority of our patients, they’ve been introduced to CPAP. They’ve tried CPAP. Maybe they’ve had some benefit with it, but they are not using CPAP, they’re not tolerant to it. And so it’s really not a big barrier for the physicians to document that those patients are unable to benefit from CPAP and are able to move forward with therapy.
Tim Herbert: So, thank you very much, Suraj. Just want to make one last note to everybody. I want to thank everybody for joining the call today. As always, I’m grateful to the growing team of dedicated Inspire employees for their enthusiasm, hard work, and continued motivation to achieve successful and consistent patient outcomes. The team’s commitment to patients remains unmatched and is the most important element to our success. I wish to thank all of our employees as well as the health care teams for their continued efforts as we remain focused on further expanding our business in the United States, in Europe, and in Asia. For all of you on the call, we appreciate your continued interest and support of Inspire and look forward to providing you with further updates in the months ahead.
Operator: This concludes today’s conference call. You may now disconnect.
